Monica Herrera is responsible for assay development of clinically relevant screening, diagnosis, and monitoring applications using Bio-Rad's digital droplet PCR technology, within the human genetics and infectious disease markets. Most recently, she launched the SARS-CoV-2 ddPCR Kit, granted EUA by FDA in May 2020 and is the focus of various clinical research collaborations due to its high sensitivity and quantitative nature. Previously, while at Roche Diagnostics, she led the development of CINtec PLUS Cytology, a first-of-its-kind immunocytochemistry duplex assay for cervical cancer screening, now recognized as part of the testing algorithm in the US and other geographies. Monica also served as the Lifecycle Project Leader for the Harmony NIPT business area, bringing that portfolio onto next-generation platforms. Monica is an accomplished Diagnostic Development professional with a scientific and medical background spanning more than 15 years; she is passionate about bringing innovative and patient-centric solutions into the clinical space.